Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States
ABSTRACT Background As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.Methods In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2.Results Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%).Conclusion During March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 05. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.07.08.21259776 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032166044 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032166044 | ||
| 003 | DE-627 | ||
| 005 | 20231205150330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210712s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.08.21259776 |2 doi | |
| 035 | |a (DE-627)XBI032166044 | ||
| 035 | |a (biorXiv)10.1101/2021.07.08.21259776 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tenforde, Mark W. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.Methods In a multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine effectiveness to prevent Covid-19 hospitalizations by comparing odds of prior vaccination with an mRNA vaccine (Pfizer-BioNTech or Moderna) between cases hospitalized with Covid-19 and hospital-based controls who tested negative for SARS-CoV-2.Results Among 1210 participants, median age was 58 years, 22.8% were Black, 13.8% were Hispanic, and 20.6% had immunosuppression. SARS-CoV-2 lineage B.1.1.7 was most common variant (59.7% of sequenced viruses). Full vaccination (receipt of two vaccine doses ≥14 days before illness onset) had been received by 45/590 (7.6%) cases and 215/620 (34.7%) controls. Overall vaccine effectiveness was 86.9% (95% CI: 80.4 to 91.2%). Vaccine effectiveness was similar for Pfizer-BioNTech and Moderna vaccines, and highest in adults aged 18-49 years (97.3%; 95% CI: 78.9 to 99.7%). Among 45 patients with vaccine-breakthrough Covid hospitalizations, 44 (97.8%) were ≥50 years old and 20 (44.4%) had immunosuppression. Vaccine effectiveness was lower among patients with immunosuppression (59.2%; 95% CI: 11.9 to 81.1%) than without immunosuppression (91.3%; 95% CI: 85.5 to 94.7%).Conclusion During March–May 2021, SARS-CoV-2 mRNA vaccines were highly effective for preventing Covid-19 hospitalizations among US adults. SARS-CoV-2 vaccination was beneficial for patients with immunosuppression, but effectiveness was lower in the immunosuppressed population. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Patel, Manish M. |4 aut | |
| 700 | 1 | |a Ginde, Adit A. |4 aut | |
| 700 | 1 | |a Douin, David J. |4 aut | |
| 700 | 1 | |a Talbot, H. Keipp |4 aut | |
| 700 | 1 | |a Casey, Jonathan D. |4 aut | |
| 700 | 1 | |a Mohr, Nicholas M. |4 aut | |
| 700 | 1 | |a Zepeski, Anne |4 aut | |
| 700 | 1 | |a Gaglani, Manjusha |4 aut | |
| 700 | 1 | |a McNeal, Tresa |4 aut | |
| 700 | 1 | |a Ghamande, Shekhar |4 aut | |
| 700 | 1 | |a Shapiro, Nathan I. |4 aut | |
| 700 | 1 | |a Gibbs, Kevin W. |4 aut | |
| 700 | 1 | |a Files, D. Clark |4 aut | |
| 700 | 1 | |a Hager, David N. |4 aut | |
| 700 | 1 | |a Shehu, Arber |4 aut | |
| 700 | 1 | |a Prekker, Matthew E. |4 aut | |
| 700 | 1 | |a Erickson, Heidi L. |4 aut | |
| 700 | 1 | |a Exline, Matthew C. |4 aut | |
| 700 | 1 | |a Gong, Michelle N. |4 aut | |
| 700 | 1 | |a Mohamed, Amira |4 aut | |
| 700 | 1 | |a Henning, Daniel J. |4 aut | |
| 700 | 1 | |a Steingrub, Jay S. |4 aut | |
| 700 | 1 | |a Peltan, Ithan D. |4 aut | |
| 700 | 1 | |a Brown, Samuel M. |4 aut | |
| 700 | 1 | |a Martin, Emily T. |4 aut | |
| 700 | 1 | |a Monto, Arnold S. |4 aut | |
| 700 | 1 | |a Khan, Akram |4 aut | |
| 700 | 1 | |a Hough, C. Terri |4 aut | |
| 700 | 1 | |a Busse, Laurence |4 aut | |
| 700 | 1 | |a ten Lohuis, Caitlin C. |4 aut | |
| 700 | 1 | |a Duggal, Abhijit |4 aut | |
| 700 | 1 | |a Wilson, Jennifer G. |4 aut | |
| 700 | 1 | |a Gordon, Alexandra June |4 aut | |
| 700 | 1 | |a Qadir, Nida |4 aut | |
| 700 | 1 | |a Chang, Steven Y. |4 aut | |
| 700 | 1 | |a Mallow, Christopher |4 aut | |
| 700 | 1 | |a Gershengorn, Hayley B. |4 aut | |
| 700 | 1 | |a Babcock, Hilary M. |4 aut | |
| 700 | 1 | |a Kwon, Jennie H. |4 aut | |
| 700 | 1 | |a Halasa, Natasha |4 aut | |
| 700 | 1 | |a Chappell, James D. |4 aut | |
| 700 | 1 | |a Lauring, Adam S. |4 aut | |
| 700 | 1 | |a Grijalva, Carlos G. |4 aut | |
| 700 | 1 | |a Rice, Todd W. |4 aut | |
| 700 | 1 | |a Jones, Ian D. |4 aut | |
| 700 | 1 | |a Stubblefield, William B. |4 aut | |
| 700 | 1 | |a Baughman, Adrienne |4 aut | |
| 700 | 1 | |a Womack, Kelsey N. |4 aut | |
| 700 | 1 | |a Lindsell, Christopher J. |4 aut | |
| 700 | 1 | |a Hart, Kimberly W. |4 aut | |
| 700 | 1 | |a Zhu, Yuwei |4 aut | |
| 700 | 1 | |a Olson, Samantha M. |4 aut | |
| 700 | 1 | |a Stephenson, Meagan |4 aut | |
| 700 | 1 | |a Schrag, Stephanie J. |4 aut | |
| 700 | 1 | |a Kobayashi, Miwako |4 aut | |
| 700 | 1 | |a Verani, Jennifer R. |4 aut | |
| 700 | 1 | |a Self, Wesley H. |0 (orcid)0000-0002-9300-3045 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 05. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.08.21259776 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 11 | ||